MILESTONE PHARMACEUTICALS ANNOUNCES FIRST EUROPEAN STUDY PARTICIPANT ENROLLED IN REVERA-301 PHASE 3 CLINICAL TRIAL

Reuters · 1d ago

Please log in to view news